Naive synthesis •	0.99	0.71	0.84	0.75	0.33	0.53	0.66	0.38	0.49	0.58	0.33	0.50	0.36	0.04	0.04	
Data based beta-No DW •	0.98	0.77	0.83	0.72	0.44	0.51	0.49	0.39	0.44	0.58	0.52	0.46	0.28	0.06	0.03	
Data based beta-RoB DW •	0.98	0.76	0.84	0.72	0.45	0.51	0.48	0.38	0.43	0.59	0.53	0.47	0.29	0.05	0.03	
Data based beta-NCT DW •	0.98	0.75	0.84	0.70	0.42	0.51	0.49	0.38	0.45	0.60	0.54	0.48	0.28	0.06	0.02	_
Expert opinion beta-No DW •	0.96	0.78	0.86	0.84	0.57	0.64	0.62	0.42	0.50	0.47	0.21	0.20	0.30	0.13	0.01	
Expert opinion beta-RoB DW •	0.95	0.78	0.86	0.84	0.57	0.64	0.62	0.43	0.50	0.46	0.22	0.20	0.29	0.13	0.01	_
Expert opinion beta-NCT DW •	0.95	0.76	0.87	0.84	0.56	0.65	0.65	0.42	0.49	0.46	0.23	0.23	0.29	0.11	0.01	
NMA with non–informative priors •	0.93	0.83	0.82	0.77	0.58	0.54	0.49	0.49	0.48	0.39	0.39	0.34	0.27	0.15	0.00	
	Clozapine	Molindone	Olanzapine	Risperidone	Lurasidone	Aripiprazole	Paliperidone	Asenapine	Quetiapine	Haloperidol	Trifluoperazine	Loxapine	Ziprasidone	Placebo	Fluphenazine	1

SUCRAS